colorectal cancer

GSK

Biotech

GSK pens $1.3B Hutchmed deal for KRAS-EGFR cancer asset

GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology asset.

Ben Adams Sep 3, 2026 7:45am

Comedy and tragedy masks on red curtain background

BioNTech, Genentech cancel ph. 2 test of personalized cancer vax

Aug 28, 2026 1:50pm

pipeline pipes RD research

PDS halts ph. 3 cancer therapy to focus on colorectal contender

Aug 13, 2026 9:55am

Guardant Health Patrick Dempsey CRC screening

Guardant taps Patrick Dempsey for colorectal cancer awareness

Jul 28, 2026 8:54am

Abbott sign

FDA approves Freenome colorectal cancer blood test

Jul 27, 2026 10:29am

Colon cancer cells magnified 400x under a microscope The cells are purple and take on spherical shapes around a round center

Agenus scraps ph. 3 colorectal study to narrow focus to colon

Jul 13, 2026 7:55am